Eli Lilly And Co (NYSE:LLY) SVP Stephen F. Fry sold 14,847 shares of the stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $123.16, for a total value of $1,828,556.52. Following the transaction, the senior vice president now directly owns 109,663 shares in the company, valued at approximately $13,506,095.08. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Shares of Eli Lilly And Co stock opened at $123.08 on Friday. The company has a debt-to-equity ratio of 1.07, a current ratio of 1.73 and a quick ratio of 1.38. The stock has a market cap of $127.87 billion, a PE ratio of 22.18, a price-to-earnings-growth ratio of 2.49 and a beta of 0.33. Eli Lilly And Co has a 1-year low of $74.51 and a 1-year high of $130.75.

Eli Lilly And Co (NYSE:LLY) last announced its earnings results on Wednesday, February 6th. The company reported $1.33 earnings per share for the quarter, missing the consensus estimate of $1.36 by ($0.03). The business had revenue of $6.44 billion for the quarter, compared to analyst estimates of $6.28 billion. Eli Lilly And Co had a net margin of 13.16% and a return on equity of 44.66%. The firm’s revenue was up 4.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.14 earnings per share. On average, analysts predict that Eli Lilly And Co will post 5.62 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Friday, March 8th. Investors of record on Friday, February 15th were paid a $0.645 dividend. This represents a $2.58 dividend on an annualized basis and a yield of 2.10%. This is an increase from Eli Lilly And Co’s previous quarterly dividend of $0.56. The ex-dividend date was Thursday, February 14th. Eli Lilly And Co’s dividend payout ratio (DPR) is 46.49%.

LLY has been the topic of several research reports. Citigroup set a $124.00 target price on Eli Lilly And Co and gave the stock a “hold” rating in a research report on Tuesday, February 26th. JPMorgan Chase & Co. initiated coverage on Eli Lilly And Co in a research report on Tuesday. They issued an “overweight” rating and a $140.00 target price on the stock. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Eli Lilly And Co in a research report on Monday, February 4th. Zacks Investment Research lowered Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Tuesday, December 4th. Finally, UBS Group lowered their price target on Eli Lilly And Co from $107.53 to $100.00 and set an “average” rating for the company in a report on Friday, February 8th. Eleven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Eli Lilly And Co has a consensus rating of “Buy” and an average price target of $113.06.

A number of large investors have recently bought and sold shares of LLY. Oregon Public Employees Retirement Fund grew its stake in Eli Lilly And Co by 17,720.8% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 42,420,406 shares of the company’s stock worth $367,000 after purchasing an additional 42,182,367 shares in the last quarter. Norges Bank acquired a new position in Eli Lilly And Co in the fourth quarter worth about $1,056,086,000. FMR LLC grew its stake in Eli Lilly And Co by 526.5% in the third quarter. FMR LLC now owns 7,444,216 shares of the company’s stock worth $798,838,000 after purchasing an additional 6,255,915 shares in the last quarter. Amundi Pioneer Asset Management Inc. grew its stake in Eli Lilly And Co by 165.4% in the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 6,012,822 shares of the company’s stock worth $695,804,000 after purchasing an additional 3,747,482 shares in the last quarter. Finally, BlackRock Inc. grew its stake in Eli Lilly And Co by 3.0% in the fourth quarter. BlackRock Inc. now owns 68,956,519 shares of the company’s stock worth $7,979,649,000 after purchasing an additional 2,030,845 shares in the last quarter. Institutional investors and hedge funds own 77.00% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Stephen F. Fry Sells 14,847 Shares of Eli Lilly And Co (LLY) Stock” was first posted by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.dailypolitical.com/2019/03/15/stephen-f-fry-sells-14847-shares-of-eli-lilly-and-co-lly-stock.html.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

See Also: Momentum Investing

Insider Buying and Selling by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.